Segall Bryant & Hamill LLC Sells 26,627 Shares of ICU Medical, Inc. (NASDAQ:ICUI)

Segall Bryant & Hamill LLC decreased its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 8.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 306,817 shares of the medical instruments supplier’s stock after selling 26,627 shares during the quarter. ICU Medical comprises 0.7% of Segall Bryant & Hamill LLC’s holdings, making the stock its 24th largest holding. Segall Bryant & Hamill LLC owned 1.25% of ICU Medical worth $47,609,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Prudential Financial Inc. raised its stake in shares of ICU Medical by 7.6% in the fourth quarter. Prudential Financial Inc. now owns 82,059 shares of the medical instruments supplier’s stock worth $12,733,000 after purchasing an additional 5,795 shares during the last quarter. Vanguard Group Inc. lifted its stake in ICU Medical by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier’s stock valued at $416,176,000 after acquiring an additional 17,805 shares in the last quarter. LPL Financial LLC boosted its holdings in ICU Medical by 2.0% during the 4th quarter. LPL Financial LLC now owns 4,816 shares of the medical instruments supplier’s stock worth $747,000 after acquiring an additional 93 shares during the last quarter. Fox Run Management L.L.C. bought a new stake in shares of ICU Medical in the 4th quarter worth $712,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of ICU Medical in the fourth quarter valued at about $714,000. Institutional investors own 96.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Tuesday, March 18th. Raymond James set a $97.00 target price on ICU Medical in a research note on Wednesday, March 12th. Finally, Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target for the company in a research report on Wednesday, December 11th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $168.67.

Insider Transactions at ICU Medical

In other news, CEO Vivek Jain sold 1,373 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $16,262,119.64. This represents a 1.30 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.70% of the stock is currently owned by company insiders.

ICU Medical Stock Performance

NASDAQ ICUI opened at $149.82 on Tuesday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The company has a market capitalization of $3.67 billion, a PE ratio of -32.78 and a beta of 0.73. ICU Medical, Inc. has a 52-week low of $93.36 and a 52-week high of $196.26. The company has a 50-day simple moving average of $155.91 and a 200 day simple moving average of $164.35.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.